Abstract A28: Evaluation of CDK12 protein expression as a novel biomarker for PARP1/2 inhibitor sensitivity in breast cancer

In conclusion, our results highlight that CDK12 is disrupted via multiple genomic mechanisms and is a potential tumor suppressor gene in breast cancer. Loss of CDK12 protein expression is seen in 9% of unselected breast cancers and 18% of triple negative breast cancers, and may be a worthwhile treatment option for triple negative patients. Routine diagnostic quantification of CDK12 protein in tumors using immunohistochemistry is feasible, making it a viable biomarker for response to PARP1/2 inhibitor therapy.Citation Format: Kalnisha Naidoo, Patty Wai, Sarah Maguire, Frances Daley, Yinyin Yuan, Emad A. Rakha, Ian O. Ellis, Christopher J. Lord, Andrew R. Green, Rachael C. Natrajan. Evaluation of CDK12 protein expression as a novel biomarker for PARP1/2 inhibitor sensitivity in breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr A28.

Source: Molecular Cancer Research - February 29, 2016 Category: Cancer & Oncology Authors: Naidoo, K., Wai, P., Maguire, S., Daley, F., Yuan, Y., Rakha, E. A., Ellis, I. O., Lord, C. J., Green, A. R., Natrajan, R. C. Tags: Genomics - Sporadic and Hereditary: Poster Presentations - Proffered Abstracts Source Type: research